Skip to main content
. 2014 Mar;5(3-4):113–126. doi: 10.18632/genesandcancer.10

Figure 1. Characterization of the effects of secreted ligands on GDC-0941 potency.

Figure 1

(A) SW48 and SW48 H1047R cells treated with DMSO, GDC-0941 alone, or GDC-0941 plus 50 ng/ml of one of 418 secreted ligands, and assayed for viability. Controls in the absence of secreted factors and in the presence or absence of GDC-0941 are shown at bottom. (B) SW48 and SW48 H1047R cells treated with GDC-0941 alone, or GDC-0941 plus 50 ng/ml of AREG, EGF, or TGFα, and assayed for viability. (C) SW48 and SW48 H1047R cells simulated with 50 ng/ml of AREG, EGF, or TGFα and treated with either DMSO or 1.5 uM of GDC-0941. After 1 hr, cell lysates were prepared and analyzed by immunoblotting for pERKT202/Y204 and pAKTT308. (D) Six colorectal cancer cell lines simulated with 50 ng/ml of EGF and treated with either DMSO or 1.5 uM of GDC-0941. After 1 hr, cell lysates were prepared and analyzed by immunoblotting for pERKT202/Y204 and pAKTT308.